hypopharyngeal cancer
Conditions
Interventions
experimental group:Toripalimab combined with concurrent chemotherapy
control group:concurrent chemotherapy
Sponsors
National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Refuse surgery or can't be operated after multidisciplinary team discussion; 2. Pathology confirmed squamous cell carcinoma; 3. Aged 18-70 years old; 4. Stage IVa/b diseases according to 8th AJCC Staging; Treatment for the first time; 5. ECOG scores <=1; 6. Without contraindication of chemotherapy, radiotherapy and immunotherapy; Adequate main organs function, including blood routine examination, liver and kidney function, coagulation and myocardial enzyme are normal; 7. Need contraception during reproductive age; 8. Can understand and sign the consent.
Exclusion criteria
Exclusion criteria: 1. Prior invasive malignancy (except cured basal cell carcinoma, carcinoma in situ of cervix, superficial bladder cancer); 2. Severe comorbidities including cardiovascular, cerebral vascular, mental disease; 3. Active infection; congenital and acquired immunodeficiency; 4. allergic to DDP or anti-PD-1 antibody; 5. women during pregnancy and lactation; 6. any other causes forcing to stop the tail, including sever toxicities, refuse following treatment schedule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect and safety; | — |
Countries
China
Contacts
Public ContactJunlin Yi
National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC
Outcome results
None listed